Trends in Cardiovascular Medicine
Volume 16, Issue 1 , Pages 25-28 , January 2006

Platelet-Derived Growth Factor–BB Transactivates the Fibroblast Growth Factor Receptor to Induce Proliferation in Human Smooth Muscle Cells

  • Esther Millette

      Affiliations

    • Current address: Trans BIO Tech, 201, Mgr Bourget, Lévis (Québec), Canada.
    • ,
  • Bernhard H. Rauch

      Affiliations

    • Current address: Universitätsklinikum Düsseldorf, Institut für Pharmakologie und Klinische Pharmakologie, Universitätsstr. 1, Building 22.21, 40225 Düsseldorf, Germany.
    • ,
  • Richard D. Kenagy
    • ,
  • Guenter Daum
    • ,
  • Alexander W. Clowes

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Alexander W. Clowes, Department of Surgery, University of Washington School of Medicine, Box 356410, 1959 NE Pacific St, Seattle, WA 98195-6410, USA. Tel.: (+1) 206-543-9890; fax: (+1) 206-616-7495.

References 

  1. Chan P, Patel M, Betteridge L, et al. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet. 1993;341:341–342
  2. Chan AK, Kalmes A, Hawkins S, et al. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J. Vasc. Surg. 2003;37:644–649
  3. Cheng GC, Briggs WH, Gerson DS, et al. Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ. Res. 1997;80:28–36
  4. Clasper S, Vekemans S, Fiore M, et al. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan–2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J. Biol. Chem. 1999;274:24113–24123
  5. Cornelison DD, Wilcox-Adelman SA, Goetinck PF, et al. Essential and separable roles for syndecan-3 and syndecan-4 in skeletal muscle development and regeneration. Genes Dev. 2004;18:2231–2236
  6. Couchman JR, Chen L, Woods A. Syndecans and cell adhesion. Int. Rev. Cytol. 2001;207:113–150
  7. Daub H, Weiss FU, Wallasch C, et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379:557–560
  8. Daum G, Hedin U, Wang Y, et al. Diverse effects of heparin on mitogen-activated protein kinase–dependent signal transduction in vascular smooth muscle cells. Circ. Res. 1997;81:17–23
  9. Evanko SP, Raines EW, Ross R, et al. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am. J. Pathol. 1998;152:533–546
  10. Forsten KE, Courant NA, Nugent MA. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J. Cell. Physiol. 1997;172:209–220
  11. Herbert JM, Clowes M, Lea HJ, et al. Protein kinase C α expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J. Biol. Chem. 1996;271:25928–25935
  12. Horowitz A, Simons M. Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase C alpha. J. Biol. Chem. 1998;273:25548–25551
  13. Jackson CL, Reidy MA. Basic fibroblast growth factor: Its role in the control of smooth muscle cell migration. Am. J. Pathol. 1993;143:1024–1031
  14. Jones SM, Kazlauskas A. Growth factor–dependent signaling and cell cycle progression. FEBS Lett. 2001;490:110–116
  15. Jones SM, Klinghoffer R, Prestwich GD, et al. PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1. Curr. Biol. 1999;9:512–521
  16. Jones M, Tussey L, Athanasou N, et al. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J. Biol. Chem. 2000;275:7964–7974
  17. Kalmes A, Vesti BR, Daum G, et al. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ. Res. 2000;87:92–98
  18. Kato M, Wang HM, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 1998;4:691–697
  19. Kinsella MG, Tran PK, Weiser-Evans MCM, et al. Changes in perlecan expression during vascular injury—role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler. Thromb. Vasc. Biol. 2003;23:608–614
  20. Kinsella MG, Irvin C, Reidy MA, et al. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis. 2004;175:51–57
  21. Kohno M, Yokokawa K, Yasunari K, et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation. 1998;98:353–359
  22. Landgren E, Eriksson A, Wennström S, et al. Induction of fibroblast growth factor receptor-1 mRNA and protein by platelet-derived growth factor BB. Exp. Cell. Res. 1996;223:405–411
  23. Lindner V, Lappi DA, Baird A, et al. Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res. 1991;68:106–113
  24. Lindner V, Olson NE, Clowes AW, et al. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J. Clin. Invest. 1992;90:2044–2049
  25. Maasch C, Wagner S, Lindschau C, et al. Protein kinase c alpha targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca(2+)](i). FASEB J. 2000;14:1653–1663
  26. Mali M, Elenius K, Miettinen HM, et al. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J. Biol. Chem. 1993;268:24215–24222
  27. Meloche S. Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition. J. Cell. Physiol. 1995;163:577–588
  28. Meloche S, Seuwen K, Pages G, et al. Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: Correlation between late phase activation and mitogenicity. Mol. Endocrinol. 1992;6:845–854
  29. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J. Cell. Physiol. 1992;151:81–93
  30. Millette E, Rauch BH, Defawe O, et al. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ. Res. 2005;96:172–179
  31. Muthukrishnan L, Warder E, McNeil PL. Basic fibroblast growth factor is efficiently released from a cytolsolic storage site through plasma membrane disruptions of endothelial cells. J. Cell. Physiol. 1991;148:1–16
  32. Nugent MA, Karnovsky MJ, Edelman ER. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ. Res. 1993;73:1051–1060
  33. Oh ES, Woods A, Couchman JR. Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J. Biol. Chem. 1997;272:11805–11811
  34. Pickering JG, Uniyal S, Ford CM, et al. Fibroblast growth factor-2 potentiates vascular smooth muscle cell migration to platelet-derived growth factor—upregulation of α2β1 integrin and disassembly of actin filaments. Circ. Res. 1997;80:627–637
  35. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884–888
  36. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159–178
  37. Pukac LA, Castellot JJ, Wright TC, et al. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul. 1990;1:435–443
  38. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237–254
  39. Rauch BH, Millette E, Kenagy RD, et al. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ. Res. 2004;94:340–345
  40. Rauch BH, Millette E, Kenagy RD, et al. Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells. J. Biol. Chem. 2005;
  41. Refson JS, Schachter M, Patel MK, et al. Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells. Circulation. 1998;97:2506–2510
  42. Rutherford C, Martin W, Salame M, et al. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis. 1997;130:45–51
  43. Sato Y, Hamanaka R, Ono J, et al. The stimulatory effect of PDGF on vascular smooth muscle cell migration is mediated by the induction of endogenous basic FGF. Biochem. Biophys. Res. Commun. 1991;174:1260–1266
  44. Segev A, Nili N, Strauss BH. The role of perlecan in arterial injury and angiogenesis. Cardiovasc. Res. 2004;63:603–610
  45. Silver PJ, Moreau JP, Denholm E, et al. Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo. Eur. J. Pharmacol. 1998;351:79–83
  46. Skaletz-Rorowski A, Pinkernell K, Sindermann JR, et al. Angiotensin AT1 receptor upregulates expression of basic fibroblast growth factor, basic fibroblast growth factor receptor and coreceptor in human coronary smooth muscle cells. Basic Res. Cardiol. 2004;99:272–278
  47. Steinfeld R, Van Den BH, David G. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface–associated syndecans and glypican. J. Cell Biol. 1996;133:405–416
  48. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15:205–213
  49. Tran PK, Tran-Lundmark K, Soininen R, et al. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ. Res. 2004;94:550–558
  50. Wang S, Ai X, Freeman SD, et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2004;101:4833–4838
  51. Weiser MCM, Grieshaber NA, Schwartz PE, et al. Perlecan regulates Oct-1 gene expression in vascular smooth muscle cells. Mol. Biol. Cell. 1997;8:999–1011
  52. Xuereb JM, Herbert JM, Sie P, et al. Effects of heparin and related sulfated polysaccharides on tissue factor expression induced by mitogenic and non-mitogenic factors in human vascular smooth muscle cells. Thromb. Haemost. 1999;81:151–156

PII: S1050-1738(05)00217-3

doi: 10.1016/j.tcm.2005.11.003

Trends in Cardiovascular Medicine
Volume 16, Issue 1 , Pages 25-28 , January 2006

Article Tools

* Image Usage & Resolution